What the research found

Researchers at the Garvan Institute conducted a randomized controlled trial in 40 adults with type 1 diabetes, comparing metformin to placebo over six months. Contrary to the original hypothesis, metformin did not improve insulin resistance—measured using sophisticated clamp studies that assess insulin sensitivity across different tissues. Blood sugar control also showed no significant differences between groups.

Despite this, participants taking metformin required approximately 12% less insulin than those on placebo to maintain comparable blood sugar levels. This was an unexpected finding that suggests metformin influences glucose metabolism through a mechanism unrelated to improving the body's insulin sensitivity. The researchers are now investigating whether metformin's effects operate through changes to the gut microbiome, which has not previously been studied in type 1 diabetes populations.

Why it matters for you

If you're managing type 1 diabetes and tracking insulin doses as a biomarker of control, this suggests a potentially straightforward intervention: metformin is inexpensive, widely available, and already prescribed off-label to thousands of people with type 1 diabetes. A 12% reduction in daily insulin requirements could meaningfully decrease injection burden and, for some, lower hypoglycaemia risk simply through reduced total dosing.

For users logging blood glucose, insulin doses, and HbA1c, adding metformin might appear as a gradual reduction in the amount needed to hit your target ranges—without necessarily indicating improved insulin sensitivity on formal testing. This distinction matters: you wouldn't expect to see changes in fasting glucose or c-peptide levels, but you might see your total daily insulin (TDI) drift downward over weeks to months.

The mechanism remains unclear, so individual responses may vary. The 12% figure is a group average; some people may see more or less benefit. This is early enough that it shouldn't replace your current regimen without discussion with your endocrinologist, but it's worth flagging as a potential adjunct if you're struggling with insulin dose escalation or the mental burden of frequent injections.

Caveats

• Small sample size: 40 participants is a modest starting point for establishing efficacy; larger trials would strengthen confidence.
• Short duration: Six months may not capture longer-term effects or identify whether the benefit plateaus.
• Mechanism unknown: The researchers don't yet know how metformin achieves the insulin-sparing effect, making it harder to predict who will benefit most.
• Off-label use: Metformin is not currently approved for type 1 diabetes; use remains at clinician discretion.
• Observational gap: The study measured insulin resistance using clamp studies (gold standard), but didn't track gut microbiome changes or other potential mediators in this cohort.